NCT01754870View on ClinicalTrials.gov

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Interventions
DRUG

Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance

Sponsors
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

University of Wisconsin, Madison

OTHER